1. Preparation and characterization of cyclodextrin nanosponges for bortezomib delivery
- Author
-
Francesco Trotta, Leila Roshangar, Fabrizio Caldera, Mitra Jelvehgari, Mohammad Mahmoudian, Hadi Valizadeh, Parvin Zakeri-Milani, and Saeideh Allahyari
- Subjects
Male ,Pharmaceutical Science ,Antineoplastic Agents ,02 engineering and technology ,in-vitro ,030226 pharmacology & pharmacy ,Bortezomib ,cyclodextrin ,nanosponge ,permeability ,03 medical and health sciences ,0302 clinical medicine ,Nanosponges ,medicine ,Animals ,Humans ,Rats, Wistar ,chemistry.chemical_classification ,Cyclodextrins ,Cyclodextrin ,technology, industry, and agriculture ,021001 nanoscience & nanotechnology ,Anticancer drug ,Rats ,chemistry ,lipids (amino acids, peptides, and proteins) ,0210 nano-technology ,medicine.drug ,Nuclear chemistry - Abstract
Bortezomib (BTZ) as an anticancer drug has been used through the injection pathway.Two types of Cyclodextrin nanosponges (CDNSs) were synthesized and studied by DLS, TEM, FTIR, and DSC instruments for BTZ delivery. Both carriers were analyzed for loading efficiencies andBoth types of CDNSs, encapsulated BTZ in their nano-porous structure, but better loading was shown in CDNS 1:4. FTIR and DSC results proved considerable encapsulation of BTZ into CDNSs. The slow and prolonged release profile was observed for CDNS 1:4 in comparison with CDNS 1:2. Based onCDNS 1:4 has the ability to be introduced as a nontoxic carrier for BTZ delivery with its high loading, controlled release manner, high cellular uptake, and permeability improvement characteristics.
- Published
- 2020